p hajian - Department of Radiation Oncology, Shahid Beheshti University
h.r mirzaei - Department of Radiation Oncology, Shahid Beheshti University
a.sh Yousefi Kashi - Department of Radiation Oncology, Shahid Beheshti University
s Hajian - PhD in reproductive health, midwifery and reproductive health Department , Shahid Beheshti University

BACKGROUND: HER2 expression has higher risk of recurrence, resistance to CMF-based chemotherapy and adjuvant endocrine therapies. In metastatic or relapsed disease if a biopsy is done, ER, PR and HER2 should be determined. Whether this is an appropriate recommendation is uncertain because of unknown importance of clinical implication for HER2 incompatibility. discordance between metastatic or relapsed and METHODS: A literature review about studying of HER2 primary breast cancers was undertaken. These reviews were done based on clinical outcomes or prognostic effects and their associations with incompatibility in HER2 expressions. disharmony was observed and RESULTS: In 31 proper studies, no definitive factor(s) promoting HER2 evidence of alteration in gain or loss of HER2 expression does not have any clear associations in DFS and OS. Patients with HER2 positive results have been benefiting from Trastuzumab although there was some conflicting data.CONCLUSION: Because of absence for any clear associations between HER2 incompatibility leading to alterations in outcomes for patients with breast cancer , we must further inquiry to find any cause and effect.

incompatibility, HER2 expression , survival, prognosis , relapse, metastasis, Trastuzumab